Dynavax Technologies Corp
Change company Symbol lookup
Select an option...
DVAX Dynavax Technologies Corp
GE General Electric Co
GTPBU Gores Technology Partners II Inc
IRBT iRobot Corp
NRG NRG Energy Inc
FRLAU Fortune Rise Acquisition Corp
BTBT Bit Digital Inc
RUMBW Rumble Equity Warrant Exp 16th Sept 2027 *W EXP 09/16/2027
RSLS ReShape Lifesciences Inc
BWA Borgwarner Inc

Health Care : Biotechnology | Small Cap Growth
Company profile

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.


Last Trade
-0.03 (-0.30%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.31 (-3.03%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

Phexxi(R) Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health

8:46 am ET July 12, 2022 (PR Newswire) Print

Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that the Journal of Therapeutic Advances in Reproductive Health has published Mechanisms of action of currently available woman-controlled, vaginally administered, non-hormonal contraceptive products, a peer-reviewed article defining and reconfirming the mechanism of action (MOA) of Phexxi(R) (lactic acid, citric acid, potassium bitartrate).


The Journal detailed and highlighted Phexxi's ability to maintain vaginal pH up to an hour before and during vaginal intercourse as a way of preventing pregnancy.

"With the current political climate causing patients and physicians to readdress access to contraception, the publication of this article is very timely," said Dr. Todd Chappell, lead author of the article and practicing obstetrician and gynecologist. "Our society benefits when women have choices and access to the best contraception for their lives and bodies. This publication highlights the unique safety and efficacy profile of Phexxi, which offers women a truly innovative, on-demand and FDA-approved method to prevent pregnancy that does not alter the natural function of the ovaries."

The publication in the Journal of Therapeutic Advances in Reproductive Health marks the second peer-reviewed journal to publish Phexxi data in 2022. Earlier this year, the Journal of Sexual Medicine published sexual satisfaction data showing that 88.7% of women using Phexxi improved or maintained their sex life.

The Company will also present new scientific data "Pregnancies by Acts of Intercourse with Vaginal Ph Modulator: Results from the AMPOWER Study," at an oral presentation during the upcoming American Society for Reproductive Medicine (ASRM) 2022 Scientific Congress & Expo, October 24-26, 2022, in Anaheim, CA.

About PhexxiPhexxi is an on-demand method of birth control used to prevent pregnancy. Phexxi is not effective when used after sex.

Important Safety Information

-- Rare cases (0.36%) of bladder and kidney infections have been reported. If you have a history of urinary tract problems that keep coming back, you should not use Phexxi.

-- Contact your healthcare provider if you are experiencing genitourinary side effects such as vaginal burning, itching, discharge, genital discomfort (including in male partners), yeast infection, urinary tract infection, or bacterial vaginosis.

-- Phexxi does not protect against sexually transmitted infections, including HIV.

For more information about Phexxi, talk to your healthcare provider and see full Product Information at www.phexxi.com.

Please report side effects by contacting Evofem Biosciences toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Intended for United States residents only.

About Evofem BiosciencesEvofem Biosciences, Inc. (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. The Company's first FDA-approved product, Phexxi(R) (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi(R) is a registered trademark of Evofem Biosciences, Inc.

Forward-Looking StatementsThis press release includes "forward-looking statements" within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, including market and other conditions, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences' assets and business are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 10, 2022. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Media ContactJack HirschfieldEvofem Biosciences, Inc.jhirschfield@evofem.com (512) 674-5163

Investor Relations ContactAmy RaskopfEvofem Biosciences, Inc.araskopf@evofem.com(917) 673-5775

SOURCE Evofem Biosciences, Inc.


View original content to download multimedia:https://www.prnewswire.com/news-releases/phexxi-mechanism-of-action-article-published-in-the-journal-of-therapeutic-advances-in-reproductive-health-301584519.html

SOURCE Evofem Biosciences, Inc.


comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.